Literature DB >> 3489622

A comparison of eosinophil-activating factor (EAF) with other monokines and lymphokines.

K J Thorne, B A Richardson, J Taverne, D J Williamson, M A Vadas, A E Butterworth.   

Abstract

Monocytes from moderately eosinophilic individuals secrete material that enhances the cytotoxic activity of eosinophils against antibody-coated schistosomula of Schistosoma mansoni. This material is not a single substance, but can be fractionated into several active components of different size and different charge. Gel filtration of mononuclear cell supernatants separated the eosinophil-activating activity into a major component of molecular mass of 40 kDa and a minor component of molecular mass of less than 10 kDa. The major component exhibited further heterogeneity on fractionation by high performance liquid chromatography. The bulk of the eosinophil-activating activity could be separated from both colony-stimulating factor (CSF) alpha activity and from tumor necrosis factor (TNF) activity. However, human recombinant CSF alpha (GM-CSF), human recombinant TNF and rabbit tumor necrosis serum all had eosinophil-activating activity when tested against schistosomula. Eosinophils were not activated by interleukin 1, interleukin 2, interferon-alpha, lipopolysaccharide or phorbol myristate acetate.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3489622     DOI: 10.1002/eji.1830160919

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  8 in total

Review 1.  Colony-stimulating factors in the pathogenesis and treatment of disease.

Authors:  D J Williamson; C G Begley
Journal:  Postgrad Med J       Date:  1987-12       Impact factor: 2.401

2.  Killing of Plasmodium falciparum by eosinophil secretory products.

Authors:  L S Waters; J Taverne; P C Tai; C J Spry; G A Targett; J H Playfair
Journal:  Infect Immun       Date:  1987-04       Impact factor: 3.441

3.  Recombinant tumour necrosis factor inhibits malaria parasites in vivo but not in vitro.

Authors:  J Taverne; J Tavernier; W Fiers; J H Playfair
Journal:  Clin Exp Immunol       Date:  1987-01       Impact factor: 4.330

4.  Human eosinophils express functional interleukin 2 receptors.

Authors:  T H Rand; D S Silberstein; H Kornfeld; P F Weller
Journal:  J Clin Invest       Date:  1991-09       Impact factor: 14.808

5.  Role of interleukin-5 in enhanced migration of eosinophils from airways of immunized guinea-pigs.

Authors:  E Coëffier; D Joseph; B B Vargaftig
Journal:  Br J Pharmacol       Date:  1994-11       Impact factor: 8.739

6.  Eosinophil-activating factor (EAF) production by a human cell line (ESH 98) stimulated with tumour necrosis factor.

Authors:  K J Thorne; B A Richardson; A E Butterworth; M Stanley
Journal:  Immunology       Date:  1988-03       Impact factor: 7.397

7.  FMLP is a potent activator of guinea-pig eosinophils but its activity is dependent on the prior overnight in vitro culture of the cells (facilitation).

Authors:  M K Bach; J R Brashler
Journal:  Immunology       Date:  1992-04       Impact factor: 7.397

8.  Stimulation of proliferation, differentiation, and function of human cells by primate interleukin 3.

Authors:  A F Lopez; L B To; Y C Yang; J R Gamble; M F Shannon; G F Burns; P G Dyson; C A Juttner; S Clark; M A Vadas
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.